Skip to content
The NDSS is administered by Diabetes Australia
Read aloud

Eligibility expansion for all people with type 1 diabetes to access subsidised CGM and Flash GM products through the NDSS

Published:

Rollout commencing 1 July 2022

Access to subsidised continuous glucose monitoring (CGM) and flash glucose monitoring (Flash GM) products through the NDSS is expanding to include all people with type 1 diabetes. This means people with type 1 diabetes aged 21 years or older who do not have concessional status will have access to subsidised CGM and Flash GM products through the NDSS. Rollout of the expansion will commence on 1 July 2022. From this date, all people with type 1 diabetes will be able to apply for access to the Australian Government’s CGM Initiative. There are no changes for people with diabetes who currently access fully subsidised CGM or Flash GM products through the NDSS.

Key information

  • Access to subsidised continuous glucose monitoring (CGM) and flash glucose monitoring (Flash GM) products through the NDSS is expanding to include all people with type 1 diabetes.
  • Rollout of the expansion will commence on 1 July 2022.
  • There are different pathways for newly eligible people registered with the NDSS to start accessing subsidised products. The exact date you can start purchasing subsidised products will depend on the pathway relevant to you.
  • Once your eligibility is confirmed, you will receive notification from the NDSS confirming access and you will be able to start purchasing subsidised products through NDSS Access Points (usually a community pharmacy).
  • For people with type 1 diabetes aged 21 years or older who do not have concessional status, the co-payment you will pay is equivalent to $32.50 per one month’s supply.

Find out more about the eligibility expansion for all people with type 1 diabetes, including helpful FAQs, and how to apply for access from 1 July 2022.